Trial Information
Visualizing VEGF Producing Lesions in Von Hippel-Lindau Disease
Inclusion Criteria:
- clinically or genetically proven VHLD
- at least 1 measurable, VHL associated lesion in the CNS
- routine MRI of the CNS ≤ 6 weeks before inclusion
- routine CT or MRI of upper abdomen ≤ 3 months before inclusion or planned ≤ 3 months
after 89Zr-bevacizumab PET scan
- age ≥ 18 years
- written informed consent must be given according to good clinical practice (GCP), and
local regulations
Exclusion Criteria:
- pregnancy
- any psychological, familial, sociological or geographical condition potentially
hampering compliance with the study protocol, those conditions should be discussed
with the patient before registration in the trial
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Detection rate of VHL associated lesions with 89Zr-bevacizumab PET scans in patients with VHLD
Outcome Time Frame:
An 89Zr-bevacizumab PET scan will be performed within 6 weeks after routine MRI CNS investigation, MRI will be repeated within 12 months.
Safety Issue:
No
Principal Investigator
Sjoukje Oosting, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University Medical Centre Groningen
Authority:
Netherlands: Medical Ethics Review Committee (METC)
Study ID:
METc2009.119
NCT ID:
NCT00970970
Start Date:
September 2009
Completion Date:
November 2012
Related Keywords:
- Von Hippel-Lindau Disease
- Hemangioblastoma
- Renal Cell Carcinoma
- Pheochromocytoma
- Pancreatic Neuroendocrine Tumor
- Vascular endothelial growth factor
- von Hippel Lindau disease
- molecular imaging
- biomarker
- Carcinoma
- Carcinoma, Renal Cell
- Von Hippel-Lindau Disease
- Pheochromocytoma
- Hemangioblastoma
- Neuroendocrine Tumors
- Adenoma, Islet Cell